BioSpace News Archive

On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis

Digirad Corporation will release financial results for its third quarter ended September 30, 2019 before the market opens on Thursday, November 14, 2019.

Baylis Medical announced the first North American use of its EPstar™ Fixed Electrophysiology Catheters.

Uncomplicated Solutions Drive Awareness, Education And Prevention

Neural Analytics, Inc. announced the first subjects enrolled with its next-generation robotic platform as part of the IRB approved CODEX study, a prospective, single arm, multi-center, safety and technical feasibility study utilizing an investigational device exemption version of the Lucid™ Robotic System, at the Ochsner Clinical Foundation in New Orleans, Louisiana.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it will release its third quarter 2019 financial results and operational highlights before open of U.S. markets on Thursday, November 7, 2019.

Collaboration includes discovery and development of additional therapies targeting multiple additional gene targets implicated in chronic HBV infection

Teleflex Incorporated announced that its Board of Directors declared a quarterly cash dividend of thirty-four cents per share of common stock.

NovaBay® Pharmaceuticals, Inc., a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial results after market close on Thursday, November 7, 2019 and will hold an investment community conference call that day.

Reported Positive Phase 3 ClarIDHy Results for TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma; sNDA Submission Planned by Year-End